Thierry Robin

ArcLight Capital Holdings LLC (ArcLight Capital) is a private equity firm founded by Dan R. Revers and Robb Eric Turner in 2000. The firm is headquartered in Boston, MA.

Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry.

Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools.

ArcLight Capital Partners LLC provides investment services. It invests in midstream, power, and production opportunities with substantial growth potential, significant current income and meaningful downside protection, typically on a proprietary basis. The company was founded by Daniel Raymond Revers and Robb Eric Turner in 2001 and is headquartered in Boston, MA.

National Society to Prevent Blindness operates as an eye health and safety organization. It offers services for amblyopia, AMD, cataract, central retinal vein occlusion, colour blindness, conjunctivitis, diabetic eye disease and macular enema, dry eye, floaters, glaucoma, refractive eye, retinal tears and detachments, retinitis pigments and strabismus. The company was founded in 1908 and is headquartered in Chicago, IL.

Mirai Medical Ltd. is an Irish medical technology company that focuses on improving cancer outcomes and enhancing patient experiences. The company is based in Oranmore, Ireland. Mirai Medical has developed a unique precision therapy platform called epore® technology, which targets tumour tissue while preserving surrounding healthy tissue structure. This technique greatly reduces side effects and improves the experience of cancer patients. Mirai Medical's epore® and endove® therapies are approved for commercialization in certain countries and are designed to provide safe and highly effective treatment of skin and gastrointestinal cancers. The company was founded in 2015 by Declan Soden, who has been the CEO since then.